View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
October 18, 2019updated 23 Oct 2019 9:57am

Alexion to acquire Achillion Pharma for $930m

Achillion is a clinical-stage biopharmaceutical company focused on the development of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases.

By GlobalData Healthcare

Alexion has entered into definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930m. Achillion is a clinical-stage biopharmaceutical company focused on the development of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G).

This deal comes as no surprise, as Alexion is a market leader for the treatment of PNH and its anti-complement C5 drug Soliris (eculizumab) is the standard of care for PNH. Soliris is one of the most expensive drugs on the market, costing around $400,000 per year and, despite its patent expiries in the US in 2021 and EU in 2020, is forecast to generate $3.4bn in 2025. The longer-acting C5 antagonist Ultromiris (ravulizumab) launched in 2018 and is forecast to generate $2.8bn in 2025. These two therapies remain the only two treatment options for PNH and account for the vast majority of Alexion’s overall revenue.

Achillion’s lead programme, danicopan (ACH-4471), is in Phase II development for PNH both as a monotherapy and in combination with Soliris for patients with suboptimal responses to Soliris. Danicopan is a first-generation small molecule inhibitor of a different part of the complement system — complement factor D — and was granted orphan drug designation and breakthrough therapy designation by the US Food and Drug Administration (FDA) in 2017 and 2019, respectively. 

Achillion is also developing a second-generation factor D inhibitor, ACH-5228, which is in Phase I development for PNH. It is hoped that inhibition of factor D production will reduce uncontrolled complement activation further upstream in the complement cascade than C5 and will leave the rest of the complement system intact, as it is a critical component of the body’s immune response.

The high value of this deal represents the commercial importance of PNH treatment to Alexion: by acquiring the rights to the promising danicopan, Alexion will be able to expand their reach to even more PNH patients.

Related reports:

GlobalData (2019). Expert Insight: Alexion’s Ultomiris Set to Replace Soliris as Standard of Care for PNH, July 2019, GDHC2519EI

GlobalData (2018). Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H1, 2018, April 2018, GDHC4940CTIDB

 

Related Companies

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology